Cited by 1,004Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta

Open access
Griciuc, Ana, Serrano-Pozo, Alberto, Parrado, Antonio R., Lesinski, Andrea N., Asselin, Caroline N., Mullin, Kristina, Hooli, Basavaraj, Choi, Se Hoon +2 more·2013·Neuron

Abstract

The transmembrane protein CD33 is a sialic acid-binding immunoglobulin-like lectin that regulates innate immunity but has no known functions in the brain. We have previously shown that the CD33 gene is a risk factor for Alzheimer's disease (AD). Here, we observed increased expression of CD33 in microglial cells in AD brain. The minor allele of the CD33 SNP rs3865444, which confers protection against AD, was associated with reductions in both CD33 expression and insoluble amyloid beta 42 (Aβ42) levels in AD brain. Furthermore, the numbers of CD33-immunoreactive microglia were positively correlated with insoluble Aβ42 levels and plaque burden in AD brain. CD33 inhibited uptake and clearance of Aβ42 in microglial cell cultures. Finally, brain levels of insoluble Aβ42 as well as amyloid plaque burden were markedly reduced in APP(Swe)/PS1(ΔE9)/CD33(-/-) mice. Therefore, CD33 inactivation mitigates Aβ pathology and CD33 inhibition could represent a novel therapy for AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuron.2013.04.014

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Microglial phagocytic capability is affected by AD risk factors such as TREM2 and CD33.

    “Phagocytic capability of microglia has been shown to be affected by risk factors for AD, such as TREM2 and CD33 (Griciuc et al., 2013; Kleinberger et al., 2014).”
  • In microglia, CD33 seems to regulate phagocytosis of amyloid-β, with a reduction in CD33 associated with increased phagocytosis.

    “In microglia, CD33 seems to regulate phagocytosis of amyloid-β, with a reduction in CD33 associated with increased phagocytosis.70”
  • CD33 expression was shown to correlate with pan-microglial markers Iba1 or CD11b, supporting its microglial localization.

    “CD33 expression was shown to correlate with pan-microglial markers Iba1 or CD11b, supporting its microglial localization.66, 70, 104”
  • Higher expression of CD33 genes or of CD33 immunolabelled cells was noted in three studies in the superior and middle temporal gyri, frontal cortex and temporal cortex of patients with Alzheimer's disease relative to controls.

    “Higher expression of CD33 genes or of CD33 immunolabelled cells was noted in three studies in the superior and middle temporal gyri, frontal cortex and temporal cortex of patients with AD relative to controls.66, 70, 104”
  • The three stereology studies that counted all microglia, identified by either Iba1 or morphology, reported no differences in total microglial counts in AD relative to control samples, whereas increases were noted in the number of cells positive for activation-associated markers MHCII, CD68 and CD33.

    “Interestingly, the three stereology studies that counted all microglia, identified by either Iba1 or morphology, reported no differences in total microglial counts in AD relative to control samples,54, 122, 70 whereas increases were noted in the number of cells positive for activation-associated markers MHCII, CD68 and CD33.54, 70, 83, 84”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E.
Affiliations
Harvard University (US)
Corresponding author
Tanzi, Rudolph E.
Venue
Neuron
Publisher
Elsevier BV
Published
2013-05
Volume
78
Issue
4
Pages
631-643
ISSN
0896-6273 (ISSN-L)
OpenAlex
W2133646735
Cited by
1,004
References
59
Citations by year
2026: 42 · 2025: 58 · 2024: 123 · 2023: 69 · 2022: 87 · 2021: 84 · 2020: 93 · 2019: 83 · 2018: 71 · 2017: 70 · 2016: 68 · 2015: 70 · 2014: 65 · 2013: 20
FWCI
51.62
Type
journal article
Language
en
Open access
Locations
  • Neuron (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Aging (5P01 AG15379, P01AG015379, AG-08487, R01AG008487, P50 AG05134, P50AG005134, T32AG000222, P30AG062421)
  • National Institute of Mental Health (R01MH060009, R37MH060009)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
CD33, Alzheimer's disease, amyloid-beta 42, microglia, amyloid clearance, amyloid plaques, genetic risk factors, APP/PS1 mice, innate immunity, sialic acid-binding lectins, therapeutic target
MeSH terms
Alzheimer Disease, Animals, Disease Models, Animal, Humans, Mice, Inbred C57BL, Mice, Transgenic, Reference Values, RNA, Messenger, Case-Control Studies, Amyloid beta-Peptides, Matched-Pair Analysis, Microglia, Mice, Knockout, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Mice, Sialic Acid Binding Ig-like Lectin 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review